Search
Menu
Home
HTB
2004
May
May 2004
Contents
Editorial
Volume 5 Number 4 May 2004
Conference reports
5th International Workshop on Clinical Pharmacology of HIV Therapy, 1-3 April 2004, Rome, Italy
Large reductions in plasma PK levels of saquinavir, amprenavir and lopinavir/r levels when given with tipranavir/ritonavir
Good generic drugs and good adherence in Rwanda
Steady state PK of nelfinavir and M8 in pregnancy
Higher nelfinavir concentrations improve response in children
PK of once daily lopinavir/r in children
2nd European HIV Drug Resistance Workshop, 11-13 March 2004, Rome, Italy
Understanding developments in HIV drug resistance for new drugs and targets — atazanavir, fusion (T-20) and receptor inhibitors
11th Conference on Retroviruses and Opportunistic Infections (CROI), 8-11 February 2004, San Francisco
HIV-associated dementia and cognitive dysfunction
Diabetes and HIV and HCV; aging/HIV and diabetes
Antiretrovirals
US treatment guidelines updated – March 2004
Atazanavir launched in UK
Tenofovir/FTC co-formulation application made to EMEA
Abacavir/3TC co-formulation available in expanded access
Treatment access
Outcomes after two years of providing antiretrovirals in Khayelitsha, South Africa
A round-up of news on access to treatments
Pregnancy
Post partum complications in HIV-positive women
Paediatric care
Children’s HIV National Network (CHINN) Review
FDA approves new paediatric dose of nelfinavir
PK and drug interactions
Eating grapefruit triggers statin-related rhabdomyolysis
Side effects
FDA panel recommends approval of New-fill
Lipodystrophy regresses in three patients switched to atazanavir
Cancer and HIV
Surgery and HAART are an effective combination for treating HPV-associated lesions
Other news
Postexposure prophylaxis does not lead to an increase in high-risk behaviour
Law would permit HIV-positive organ donation
A guide to applying to the Global Fund is released
On the web
Conference reports
Online medical training
Newletters and journals
PDFs
Volume 5 Number 4 May 2004 PDF
HTB RSS
Early access
Kigala Call to Action: sign-on for IAS 2025 conference
1 July 2025
HIV organisations support trans and non-binary communities against the unworkable EHRC guidelines
30 June 2025
Long-acting injectable PrEP approved in the US: priced at $28,000 a year
28 June 2025
Clinical studies of two once-weekly pipeline compounds put on hold
27 June 2025
All early access reports
Current issues
July 2025
June 2025
May 2025
Back issues
Special report
Kigala Call to Action: sign-on for IAS 2025 conference
1 July 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate